Artritis Reumatoid | 083808490070 | Uji Klinis Transfer Factor

SOME CLINICAL ABSTRACT OF USING TRANSFER FACTOR FOR RHEUMATOID ARTHRITIS PATIENTS

Med Interne 1985 Apr-Jun;23(2):135-40

Effect of long-term therapy with transfer factors in rheumatoid arthritis

Georgescu C.

Specific immunotherapy with transfer factors was used in a chronic experiment in a group of 50 female patients with rheumatoid arthritis (RA) stage I-III. The patients were followed up for 24 months, clinical and biologic examinations being repeated every 3 months. In this period the patients received beside the basic nonsteroid anti-inflammatory therapy, one unit transfer factors every week over a period of 6 months then one until transfer factors every month (10 patients) to the end of experiment. Of the 50 patients 15 (30%) did not respond to the therapy and the experiments had to be interrupted after 6 months. Excellent, very good and good results were obtained in 35 patients (70%). In 12 patients the response was good but the dose of transfer factors had to be increased to two units/week in the first 6 months. In 13 patients the results obtained were very good and therapy with nonsteroid products + transfer factors was continued even after the first 6 months. In 10 patients with RA stage I the results obtained were excellent and after 6 months the nonsteroid therapy could be interrupted and the therapy was continued only with one unit transfer factors every month. The study confirmed the fact that specific immunotherapy with transfer factors represents an important adjuvant in the treatment of rheumatoid arthritis (RA).

Influence of various forms of dialyzable leukocyte extracts on rat adjuvant arthritis

(Dialyzable leukocyte is another term for transfer factors)

Stancikova M, Rovensky J, Pekarek J, Orvisky E, Blazickova S,

Cech K. Research Institute of Rheumatic Diseases, Slovak Republic.

Adjuvant-induced arthritis in rats is a chronic inflammatory disease, widely used as an animal model for rheumatoid arthritis. In our study the effect of various fractions of dialyzable leukocyte extract (DLE): DLE I-molecular weight below 10 kDa (commercial preparation), DLE II-molecular weight below 5 kDa (suppressor fraction), DLE III-molecular weight 5-10 kDa on rat adjuvant-induced arthritis was studied. The adjuvant arthritic (AA) rats were treated with DLE fraction i.p. in solutions containing an active substance isolated from 12.5 x 10(6) and 6.25 x 10(6) leukocytes from day 1 (adjuvant injected) through day 18, every second day (total 9 times). Various markers of inflammation, immune function and joint destruction were evaluated: hindpaw volume, serum hyaluronic acid, serum albumin and biopterin in urine. All these markers showed a significant improvement after using fraction DLE II in comparison with AA controls. Fractions DLE I and DLE III influenced only some markers of inflammation and immune function. Our results demonstrated a therapeutical effect of fraction DLE II on rat adjuvant-induced arthritis Arch Immunol Ther Exp (Warsz). 1994; 42(4): 295-9.